This study aims to evaluate the effectiveness of weekly administration of isotretinoin (40 mg) in increasing sperm production in men with oligozoospermia, a condition characterized by a low sperm count. Participants will be randomized into two groups: one receiving isotretinoin and the other a placebo. The primary outcome will be the change in sperm production over 20 weeks of treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
100
ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia. The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.
placebo administration
CECOS Alsace Strasbourg
Schiltigheim, France
Millions of Sperm Per Ejaculate
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
Time frame: Day 0
Millions of Sperm Per Ejaculate
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
Time frame: Months 2
Millions of Sperm Per Ejaculate
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
Time frame: Months 5
Millions of Sperm Per Ejaculate
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
Time frame: Months 12
Millions of Sperm Per Ejaculate
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
Time frame: Months 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.